Drugs acting on the respiratory tract

Bousquet, 2002, Modulite®: simplifying the change-over, Respir Med, 96, S1, 10.1016/S0954-6111(02)80017-8 Wysowski, 2002, Use of inhalant medications with and without chlorofluorocarbon propellants in the United State, 1996–2000, J Allergy Clin Immunol, 110, 51, 10.1067/mai.2002.125001 Ganderton, 2002, Modulite®: a means of designing the aerosols generated by pressurized metered dose inhalers, Respir Med, 96, S3, 10.1016/S0954-6111(02)80018-X Woodcock, 2002, Modulite® technology: pharmacodynamic and pharmacokinetic implications, Respir Med, 96, S9, 10.1016/S0954-6111(02)80019-1 Anderson, 2002, Equivalent efficacy and safety of a new HFA-134a formulation of BDP compared with the conventional CFC in adult asthmatics, J Investig Allergol Clin Immunol, 12, 107 Vondra, 2002, A new HFA-134a propellant in the administration of inhaled BDP via the Jet spacer: controlled clinical trial vs the conventional CFC, Respir Med, 96, 784, 10.1053/rmed.2002.1348 Woodcock, 2002, Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant, J Aerosol Med, 15, 407, 10.1089/08942680260473489 Nolting, 2002, Multiple-dose proportionality study of flunisolide hydrofluoroalkane, 23, 311 Nayak, 2002, Efficacy and safety of beclomethasone dipropionate extrafine aerosol in childhood asthma, Chest, 122, 1956, 10.1378/chest.122.6.1956 Hawksworth, 2002, Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction, Ann Allergy Asthma Immunol, 88, 473, 10.1016/S1081-1206(10)62385-X Langley, 2002, A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients, Ann Allergy Asthma Immunol, 88, 488, 10.1016/S1081-1206(10)62387-3 Allen, 2002, Sense and sensitivity: assessing inhalted corticosteroid effects on the hypothalamic-pituitary-adrenal axis, Ann Allergy Asthma Immunol, 89, 537, 10.1016/S1081-1206(10)62097-2 Nelson, 2002, A comparison of methods assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma patients treated with inhaled corticosteroids, J Clin Pharmacol, 42, 319, 10.1177/00912700222011355 Fink, 2002, Hypothalamic-pituitary-adrenal axis function after inhaled corticosteroids: unreliability of urinary free corticol estimation, J Clin Endocrinol Metab, 87, 4541, 10.1210/jc.2002-020287 Goldberg, 2002, Adrenal suppression in asthmatic children receiving low-dose inhaled budesonide: comparison between dry powder inhaler and pressurized metered-dose inhaler attached to a spacer, Ann Allergy Asthma Immunol, 89, 566, 10.1016/S1081-1206(10)62103-5 Irani, 2002, Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma, Ann Allergy Asthma Immunol, 88, 306, 10.1016/S1081-1206(10)62013-3 Eid, 2002, Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate, Pediatrics, 109, 217, 10.1542/peds.109.2.217 Martin, 2002, Systemic effect comparisons of six inhaled corticosteroid preparations, Am J Respir Crit Care Med, 165, 1377, 10.1164/rccm.2105013 Lipworth, 1999, Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis, Arch Intern Med, 159, 941, 10.1001/archinte.159.9.941 Tukiainen, 2002, Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid-treated asthma patients, Respir Med, 96, 221, 10.1053/rmed.2001.1261 Skoner, 2002, Balancing safety and efficacy in pediatric asthma management, Pediatrics, 109, 381 Allen, 2002, Safety of inhaled corticorteroids in children, Pediatr Pulmonol, 33, 208, 10.1002/ppul.10040 Drake, 2002, Symptomatic adrenal insufficiency presenting with hypoglycemia in asthmatic children with asthma receiving high dose inhaled fluticasone propionate, Br Med J, 324, 1081, 10.1136/bmj.324.7345.1081 Todd, 2002, Acute adrenal crisis in asthmatics treated with high-dose fluticasone-propionate, Eur Resp J, 19, 1207, 10.1183/09031936.02.00274402 Dunlop, 2002, Hypoglycemia due to adrenal suppression secondary to high-dose nebulized corticosteroid, Pediatr Pulmonol, 34, 85, 10.1002/ppul.10132 Kennedy, 2002, Impaired recovery of hypothalamic-pituitary-adrenal axis function and hypoglycemic sezizures after high-dose inhaled corticosteroid therapy in a toddler, Ann Allergy Asthma Immunol, 88, 523, 10.1016/S1081-1206(10)62393-9 Todd, 2002, Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom, Arch Dis Child, 87, 457, 10.1136/adc.87.6.457 Kannisto, 2000, Adrenal suppression, evaluated by a low-dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled corticosteroids, J Clin Endocrinol Metab, 85, 652, 10.1210/jc.85.2.652 Shimada, 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J Pharmacol Exp Ther, 270, 414 Derendord, 1998, Pharmacokinetics and pharmacodynamics of inhaled corticosteroids, J Allergy Clin Immunol, 101, S440, 10.1016/S0091-6749(98)70156-3 Onhoj, 2000, Lung deposition of inhaled drugs increases with age, Am J Respir Crit Care Med, 162, 1819, 10.1164/ajrccm.162.5.2002132 Russel, 2002, Inhaled corticosteroids and adrenal insufficiency, Arch Dis Child, 87, 455, 10.1136/adc.87.6.455 Russel, 1994, Fluticasone propionate in children, Respir Med, 88, 3 Bousquet, 2002, A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma, Clin Ther, 24, 1, 10.1016/S0149-2918(02)85002-0 Sizonenko, 2002, Effects of inhaled or nasal glucocorticosteroids on adrenal function and growth, J Pediatr Endocrinol Metab, 15, 5, 10.1515/JPEM.2002.15.1.5 LoCascio, 1990, Bone loss in response to long-term glucocorticoid therapy, Bone Miner, 8, 39, 10.1016/0169-6009(91)90139-Q Price, 2002, Evaluating the effects of asthma therapy of childhood growth: principles of study design, Eur Respir J, 19, 1167, 10.1183/09031936.02.00249202 Price, 2002, Evaluating the effects of asthma therapy on childhood growth: what can be learnt from the published literature, Eur Respir J, 19, 1179, 10.1183/09031936.02.00288702 Wolthers, 2002, Growth problems in children with asthma, Horn Res, 57, 83, 10.1159/000058107 Wolthers, 2002, Inhaled corticosteroids, growth and compliance, New Engl J Med, 347, 1210, 10.1056/NEJM200210103471522 Allen, 2002, Inhaled corticosteroid therapy for asthma in preschool children: growth issues, Pediatrics, 109, 373 Wong, 2002, Effects of asthma and asthma therapies on bone mineral density, Curr Opin Pulm Med, 8, 39, 10.1097/00063198-200201000-00007 Bahceciler, 2002, Inhaled corticosteroids and bone density of children with asthma, J Asthma, 39, 151, 10.1081/JAS-120002196 Agertoft, 1998, Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide, Am J Respir Crit Care Med, 157, 178, 10.1164/ajrccm.157.1.9707072 Ma, 2002, Clinical risk factors but not bone density are associated with prevalent frarctures in prepubertal children, J Pediatr Child Health, 38, 497, 10.1046/j.1440-1754.2002.00037.x Johnell, 2002, Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler®, Eur Respir J, 19, 1058, 10.1183/09031936.02.00276602 2000, Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease, New Engl J Med, 343, 1902, 10.1056/NEJM200012283432601 Hubbard, 2002, Inhaled corticosteroids and hip fracture: a population-based case-control study, Am J Respir Crit Care Med, 166, 1563, 10.1164/rccm.200206-606OC Dendukurri, 2002, Inhlated corticosteroids and the risk of diabetes among the elderly, Br J Clin Pharmacol, 54, 59, 10.1046/j.1365-2125.2002.01610.x Blackburn, 2002, Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly, J Gen Intern Med, 17, 717, 10.1046/j.1525-1497.2002.10649.x Isaksson, 2002, Allergic contact dermatitis in response to budesonide reactivated by inhalation of the allergen, J Am Acad Dermatol, 46, 880, 10.1067/mjd.2002.120464 Raaska, 2002, Plasma concentration of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole, Clin Pharmacol Ther, 72, 362, 10.1067/mcp.2002.127397 Clevenbergh, 2002, Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen, J Infect, 44, 194, 10.1053/jinf.2001.0928 Lanham, 1984, Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome, Medicine, 63, 65, 10.1097/00005792-198403000-00001 Lilly, 2002, Asthma therapies and Churg-Strauss syndrome, J Allergy Clin Immunol, 109, S1, 10.1067/mai.2002.120854 Churg, 1995, Formes frustes of Churg-Strauss syndrome, Chest, 108, 320, 10.1378/chest.108.2.320 Guilpain, 2002, Churg-Strauss syndrome in two patients receiving montelukast, Rheumatology, 41, 535, 10.1093/rheumatology/41.5.535 Solans, 2002, Montelukast and Churg-Strauss syndrome, Thorax, 57, 183, 10.1136/thorax.57.2.183 Gal, 2002, Cutaneous lesions of Churg-Strauss syndrome associated with montelukast therapy, Br J Dermatol, 147, 618, 10.1046/j.1365-2133.2002.48839.x Soy, 2002, Vasculitis induced by zafirlukast therapy, Clin Rheumatol, 21, 328, 10.1007/s100670200086 Richeldi, 2002, Churg-Strauss syndrome in a case of asthma, Allergy, 57, 647, 10.1034/j.1398-9995.2002.23618.x Jamaleddine, 2002, Leukotriene antagonists and the Churg-Strauss syndrome, Semin Arthritis Rheum, 31, 218, 10.1053/sarh.2002.27735 Masi, 2002, Leukotriene antogonists: bystanders or cause of Churg-Strauss syndrome?, Semin Arthritis Rheum, 31, 211, 10.1053/sarh.2002.30439 Loughlin, 2002, Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients, Ann Allergy Asthma Immunol, 88, 319, 10.1016/S1081-1206(10)62015-7 Cobb, 2002, High-dose montelukast exposures in a 3-year old and a 5-year old child, Vet Hum Toxicol, 44, 91 Muijsers, 2002, Montelukast: a review of its therapeutical potential in asthma in children 2 to 14 years of age, Pediatr Drugs, 4, 123, 10.2165/00128072-200204020-00005 Wilton, 2002, A post-marketing surveillance study of formoterol (Foradil®), Drug Saf, 25, 213, 10.2165/00002018-200225030-00006 Sears, 2002, Adverse effects of beta-agonists, J Allergy Clin Immunol, 110, S322, 10.1067/mai.2002.129966 Hadjikoumi, 2002, Bronchodilator therapy and hyperactivity in preschool children, Arch Dis Child, 86, 202, 10.1136/adc.86.3.202 Stratakos, 2002, Tratment lactic acidosis as a side effect of inhaled salbutamol, Chest, 122, 385, 10.1378/chest.122.1.385 Prakash, 2002, Lactic acidosis in asthma: report of two cases and review of the literature, Can Respir J, 9, 203, 10.1155/2002/368695 Hellier, 2002, Reversible selective beta2-adrenoceptor-agonist-induced myopathy, Rheumatology, 41, 111, 10.1093/rheumatology/41.1.111 Kinali, 2002, Pilot trial of albuterol in spinal muscular atrophy, Neurology, 59, 609, 10.1212/WNL.59.4.609 Habib, 2002, Diabetic ketoacidosis associated with oral salbutamol overdose, Am J Med, 113, 701, 10.1016/S0002-9343(02)01294-9 Yilmaz, 2002, Salbutamol intoxication: is salbutamol a fever-inducing drug? A case report and treatment strategy, Eur J Emerg Med, 9, 179, 10.1097/00063110-200206000-00016 Herskowitz, 2002, Acute paraparesis due to terbutaline sulfate, South Med J, 95, 275, 10.1097/00007611-200202000-00026 Hvizdos, 2002, Tiotropium bromide, Drugs, 62, 1195, 10.2165/00003495-200262080-00008 Disse, 1999, Tiotropium (SpirivaTM): mechanistical considerations and clinical profile in obstructive lung disease, Life Sci, 64, 457, 10.1016/S0024-3205(98)00588-8 Beeh, 2002, Anticholinergics in the treatment of chronic obstructive pulmonary disease, Respiration, 69, 372, 10.1159/000063278 Chodosh, 2001, Effective delivery of particles with the HandiHaler® dry powder inhalation system over a range of chronic obstructive pulmonary disease severity, J Aerosol Med, 14, 309, 10.1089/089426801316970268 Van Noord, 2002, Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease, Eur Respir J, 19, 639, 10.1183/09031936.02.00238002 Casaburi, 2002, A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease, Eur Respir J, 19, 217, 10.1183/09031936.02.00269802 Vincken, 2002, Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium, Eur Respir J, 19, 209, 10.1183/09031936.02.00238702 Donohue, 2002, A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol, Chest, 122, 47, 10.1378/chest.122.1.47